ReviewJournal of Cancer2017
Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic.
Review in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma.Genes & diseases · 2024Review
- Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer.Cell death & disease · 2024Article
- PAXgene Fixation for Pancreatic Cancer: Implications for Molecular and Surgical Pathology.Journal of clinical medicine · 2022Article
- Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach.World journal of gastroenterology · 2021Review
- Drivers of Gene Expression Dysregulation in Pancreatic Cancer.Trends in cancer · 2021Review
- Predicting tissue-specific gene expression from whole blood transcriptome.Science advances · 2021Article
- Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies.Oncotarget · 2021Article
- Review
- Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.Journal of clinical medicine · 2020Review
- Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.United European gastroenterology journal · 2020Article
- Carboxypeptidase E-∆N Promotes Proliferation and Invasion of Pancreatic Cancer Cells via Upregulation of CXCR2 Gene Expression.International journal of molecular sciences · 2019Article
- Article
- Pancreatic cancer in young adults: changes, challenges, and solutions.OncoTargets and therapy · 2019Review
- Article
- Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells.Frontiers in pharmacology · 2019Review
- Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.Frontiers in oncology · 2019Article
- Pancreatic cancer subtypes: a roadmap for precision medicine.Annals of medicine · 2018Review
- IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains one of the most lethal malignancies, and insights into both personalized diagnosis and intervention of this disease are urgently needed. The rapid development of sequencing technologies has enabled the successive completion of a series of genetic and epigenetic sequencing studies of pancreatic cancer. The mutational landscape of pancreatic cancer is generally portrayed in terms of somatic mutations, structural variations, epigenetic alterations and the core signaling pathways. In recent years, four significant molecular subtype classifications of pancreatic cancer have been proposed based on the expression of transcription factors and downstream targets or the distribution of structural rearrangements. Increasing researches focus on the identification of somatic mutations and other genetic aberrations that drive pancreatic cancer has led to a new era of precision medicine based on molecular subtyping. However, few known molecular classifications are used to guide clinical strategies. Specific scientific, regulatory and ethical challenges must be overcome before genomic and transcriptomic discoveries can be translated into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.